Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome

JAMA

Volumn 299, Issue 5, 2008, Pages 532-539

  Ho, P Michael ^a,b,e   Peterson, Eric D ^c   Wang, Li ^d   Magid, David J ^b,e   Fihn, Stephan D ^d   Larsen, Greg C ^f   Jesse, Robert A ^a,g   Rumsfeld, John S ^a,b,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e KAISER PERMANENTE   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG FATALITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; CAUSE OF DEATH; CLUSTER ANALYSIS; MIDDLE AGED; MORTALITY; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT WITHDRAWAL;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAUSE OF DEATH; CLUSTER ANALYSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TICLOPIDINE; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 38949209538     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.5.532     Document Type: Article

References (33)

1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
2. Mehta SR, Yusuf S, Peters RJ, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-533.
3. Steinhubl SR, Berger PB, Mann JT III, et al; Clopidogrel for the Reduction of Events During Observation (CREDO) Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411- 2420.
4. Anderson JL, Adams CD, Antman EM, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50(7):el-el57.
5. Lauer MA, Houghtaling PL, Peterson JG, et al; Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using integrilin Therapy (PURSUIT) trial. Circulation. 2001;104(23):2772-2777.
6. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation. 1995;91(7):1929-1935.
7. Collet JP, Montalescot G. Premature withdrawal and alternative therapies to dual oral antiplatelet therapy. Eur Heart J. 2006;8(suppl):G46-G52.
8. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217-1220.
9. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45(3):456-459.
10. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes [published online ahead of print October 11, 2004]. Circulation. 2004;110(16):2361-2367.
11. Burger W, Chemnitius JM, Kneissl GD, Racker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399-414.
12. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease [published online ahead of print October 19, 2006]. Eur Heart J. 2006;27(22):2667-2674.
13. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97(3):251-256.
14. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327(3):141-145.
15. Holmes DR Jr, Kereiakes DJ, Laskey WK, et al. Thrombosis and drug-eluting stents: an objective appraisal [published online ahead of print May 22, 2007]. J Am Coll Cardiol. 2007;50(2):109-118.
16. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc. 2007;138(5):652-655.
17. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study [published online ahead of print May 22, 2007]. J Am Coll Cardiol. 2007;50(2):138-145.
18. Maynard C, Lowy E, Rumsfeld J, et al. The prevalence and outcomes of in-hospital acute myocardial infarction in the Department of Veterans Affairs Health System. Arch Intern Med. 2006;166(13):1410-1416.
19. Sohn MW, Zhang H, Arnold N, et al. Transition to the new race/ethnicity data collection standards in the Department of Veterans Affairs. Popul Health Metr. 2006;4:7.
20. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26(8):814-823.
21. Caetano PA, Lam JM, Morgan SG. Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther. 2006;28(9):1411-1424.
22. Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol. 2002;12(7):462-468.
23. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs. Popul Health Metr. 2006;4:2.
24. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14(9):555-558.
25. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 2006;55(3):780-784.
26. Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med. 2006;119(8):707.e11-707.e16.
27. Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Int J Clin Pract. 2006;60(7):863-866.
28. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
29. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
30. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published online ahead of print December 28,2006]. Circulation. 2007;115(5):e69-e171.
31. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
32. Diener HC. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-337.
33. Campo G, Valgimigli M, Gemmati D, et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? evidence from a clopidogrel-toticlopidine crossover study [published online ahead of print September 4, 2007]. J Am Coll Cardiol. 2007;50(12):1132-1137.